Genelux Investor Presentation Deck

Validating Industry Collaboration with Newsoara BioPharma Co., Ltd Key Takeaways • Newsoara will fund the US-based Genelux Phase 2 trial in NSCLC • Newsoara has development and commercialization rights in Greater China • Interim readout for one or more systemic administration trials expected as early as mid-2024 GENELUX Sponsor G NEWSCARA Trial Sites US China Systemic Program: Clinical Trials Indication Adjuvant Maintenance NSCLC Recurrent SCLC Recurrent OC Recurrent NSCLC Clinical Stage Phase II Phase I/II Phase I/II Phase I/II Patients (est.) ~138 -150 ~150 ~ 150 Randomization 2:1 Single Arm 2:1 2:1 Status Regulatory Submission Enrolling Regulatory Submission Planned Genelux will have worldwide commercial rights (excluding Greater China) to all data generated from clinical trials of Olvi-Vec in China. 22

View entire presentation